>>> Europe : Brokers Upgrades & Downgrades - 2nd of May 2023

>>> Up
* Aker BioMarine ASA Raised to Buy at DNB Markets; PT 45 kroner
* Atlas Copco Raised to Reduce at AlphaValue/Baader
* Bioretec Raised to Accumulate at Inderes; PT 2.70 euros
* Electrolux Raised to Buy at SEB Equities; PT 190 kronor
* Kitron Raised to Buy at Arctic Securities; PT 52 kroner
* Manitowoc Co Raised to Equal-Weight at Wells Fargo; PT $17
* Raute Raised to Accumulate at Inderes; PT 12 euros
* Rightmove Raised to Buy at HSBC; PT 645 pence
* Sanoma Raised to Accumulate at Inderes; PT 8.50 euros
* SCA Raised to Buy at Handelsbanken
* Schibsted Raised to Buy at Nordea; PT 260 kroner
* SGL Raised to Buy at Deutsche Bank; PT 13 euros
* SGS Raised to Outperform at RBC; PT 90 Swiss francs
* Stora Enso Raised to Overweight at JPMorgan; PT 12.60 euros
* SwedenCare Raised to Buy at Handelsbanken
* Terveystalo Raised to Buy at SEB Equities; PT 9.20 euros
* Terveystalo Raised to Buy at Inderes; PT 9 euros
* Tobii Dynavox Raised to Buy at ABG; PT 35 kronor
* Tomra Raised to Hold at ABG; PT 160 kroner
* UPM-Kymmene Raised to Overweight at JPMorgan; PT 32.20 euros

>>> Down
* Evolution Cut to Neutral at Citi
* Exxon Cut to Neutral at Goldman; PT $125
* Lemonsoft Cut to Reduce at Inderes; PT 7.70 euros
* QT Group Cut to Reduce at Inderes; PT 78 euros
* Tomra Cut to Sell at Nordea; PT 136 kroner
* Sanofi Cut to Sell at Deutsche Bank; PT 90 euros

>>> Initiation
* Believe Rated New Buy at Stifel; PT 18.50 euros
* Ence Reinstated Sponsored at BNPP Exane
* Linde Rated New Outperform at BNPP Exane; PT $398
* SGS Rated New Outperform at Credit Suisse; PT 100 Swiss francs

>>> call
* Dell Tech and HP Inc. Upgraded at Morgan Stanley on PC Rebound
* Evolution Downgraded to Neutral at Citi on Limited Upside

>>> What to look at today -2nd of May 2023

Australia’s dollar jumped after the central bank unexpectedly raised interest rates. Asian stocks fluctuated as traders assessed China data and weighed risk before a Federal Reserve meeting this week.  Shares in Australia extended losses along with the nation’s bonds as Reserve Bank of Australia hiked its benchmark rate by 25 basis points to 3.85%, an outcome forecast by only nine of 30 economists surveyed by Bloomberg. The RBA said inflation remained too high and some further tightening of monetary policy may be required. MSCI Inc.’s Asia Pacific Index of shares swung between gains and losses in a choppy trading as traders parsed a surprise contraction in China manufacturing against upbeat holiday spending data. Chinese markets are shut Tuesday and will reopen Thursday after a five-day holiday. Bloomberg’s dollar index ticked lower, while Treasuries edged up in Asia after being sold across the curve Monday. Swap traders have slightly upgraded the odds the Fed will raise its policy rate by a quarter point Wednesday, but now only expect rate cuts to happen in the later part of this year. China’s official manufacturing purchasing managers’ index fell to 49.2 in April, according to data released Sunday, feeding concerns that the economy may struggle to sustain growth momentum. Still, initial data from the Golden Week holiday showed strong travel, shopping and casino spending. 
Payment misses by Chinese developers added to the cloudy outlook, with a gauge of real estate companies dropping 1.8%.
US Treasury Secretary Janet Yellen told lawmakers on Monday that the nation risked default as soon as June 1. That came amid a high-stakes game of chicken in Washington over the debt limit. Elsewhere, oil and gold steadied.

Nikkei +0.22% Hang Seng +0.09% CSI +1.02% Shanghai +1.14% Shenzen +1.41%

Eur$ 1.0987 CNH 6.9543 CNY 6.9148 JPY 137.72 GBP 1.2504 CHF 0.8956 RUB 80.3325 TRY 19.4607 WTI$ 75.64 -0.03% Gold 1,982.45 -0.03% BTC 27,953 +0.98% ETH 1,828 +1.12%

S&P -0.03% Nasdaq +0.01% EuroStoxx +0.16% FTSE +0.25% Dax +0.15% SMI +0.29%

Macro :
- Chinese factory activity declines in April on weak global consumption
- France’s Rating Cut to AA- From AA by Fitch on Deficits, Debt
- KWG Misses Payments, Triggers 31.2B Yuan of Cross Defaults

Keep an eye on :
- ADS GY : Adidas shareholders launch class action lawsuit over Kanye West brand Yeezy
- AD NA : Ahold Delhaize Names Jolanda Poots-Bijl New CFO
- ALSN SW : ALSO CEO Gustavo MöLler-Hergt to Step Down in 2024
- AOX GY : Alstria Office 1Q FFO EU25.4M Vs. EU27.5M Y/y
- AMS SW : AMS-Osram 2Q Revenue Forecast Misses Estimates
- BP/ LN : BP 1Q Adjusted Ebit Beats Estimates
- BP/ LN : Shell Australia to Sell Stake in Browse Gas Project to BP
- CA FP : *CARREFOUR: CONTINUATION SHARE BUYBACK FOR MAX. AMOUNT OF €800M
- DBK GY : Deutsche Bank Plans to Expand Investment Bank Advisory Team: FT
- DSM NA : DSM 1Q Adjusted Ebitda EU278M Vs. EU367M Y/y
- ENEL IM : Frontis Urges Enel Shareholders to Reject Government’s Slate
- ENGI FP ; TCC’s NHOA to Propose Raising EU250m Via Converts or Rights
- ENX FP : SIX Swiss Exchange Expands Offering to Aid the Buy Side
- RE US : Everest Re 1Q Operating EPS Misses Estimates
- XOM US : Guyana to Pump 30% More Oil Than Exxon’s Forecast, Goldman Says
- EXO NA : Agnelli’s Exor Looking for More Luxury Acquisitions: Miss Tweed
- GEBN SW : Geberit 1Q Ebitda Beats Estimates
- GLEN LN : Teck Gets Court’s Approval for Multiple Voting Rights Sunset
- HSBA LN : HSBC 1Q Pretax Profit Beats Estimates
- IPCO SS : Intl Petroleum 1Q Net Income $39.6M Vs. $80.8M Y/y
- ISEE US : Astellas to Pay $40/Share in Cash for Iveric Bio: M&A Snapshot
- BAER SW : Julius Baer Names Ex-UBS Exec Aline Pacheco as SEAsia Team Head
- 1813 HK : KWG Misses Payments, Triggers 31.2B Yuan of Cross Defaults --> -22.3% in HK
- LAND SW : Landis + Gyr FY Adjusted Ebitda Beats Estimates
- LOGN SW : Logitech 4Q Adjusted EPS Beats Estimates
- MC FP : Armed Robbers Raid Bulgari Jewelry Store in Paris
- MEDCL FP : Teva, MedinCell Say FDA Approves Uzedy for Schizophrenia
- MBG GY : German-China Decoupling an ‘Illusion,’ Mercedes CEO Tells Bild
- NTI NO : Norsk Titanium Seeks to Raise Up to $45m in Private Placement
- PSH NA : Pershing Square Holdings April Net Performance +0.6%
- RWAY IM : Rai Way Board Appoints Roberto Cecatto as CEO
- REP SM : Repsol Ends Sinopec Spat With $2.1 Billion Buyout of UK Venture
- RXL FP : Rexel Levers Are Critical for Margin as Volume, Price Risks Loom
- SL IM : Sanlorenzo Signs Binding Offer to Buy Duerre’s Majority Stake
- SBMO NA : SBM Offshore in Pact for Guyana FPSO With ExxonMobil Guyana
- SAE GY : Shop Apotheke 1Q Adjusted Ebitda EU8.76M Vs. Loss EU4.28M Y/y
- GLE FP : SocGen's 25% Cost of Equity, 0.3x Book Needs More Than 1Q Bounce
- SOW GY : Bain Builds Software AG Stake in Challenge to Silver Lake
- STM GY : Stabilus 2Q Adjusted Ebit Meets Estimates
- SDRY LN : Superdry in Talks for a £15m Cash Call: Sky News
- TTE FP : Total Chief Says Europe Listing Reason for Trading Discount: FT
- ULVR LN : Ben & Jerry’s Agrees to Terms of Union at Vermont Store
- VIV FP : Hollywood Writers Set to Strike As Talks With Studios Collapse

>>> US After Hours Summary: WWD +16.6%, ZI +5.5%, NXPI +4.2% up on earnings; BB

After Hours Summary: WWD +16.6%, ZI +5.5%, NXPI +4.2% up on earnings; BB +8.5% up on strategic review of its businesses; CHGG -32.3%, ANET -7.6%, SYK -5.3% down on earnings

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: WWD +16.6%, SFM +7.1%, SIBN +6.2%, FLS +5.9%, ZI +5.5%, TEX +5.3%, NXPI +4.2%, LEG +3.6%, VNOM +2.9%, AMRC +2.4%, TMDX +2.4%, SON +2.1%, PDM +1.8%, AMKR +1.5%, LSCC +1.1%, MSTR +1.1%, KIDS +1%, MSA +0.7%, AL +0.6%, MGM +0.6%, HOLX +0.4%, RIG +0.2%, CF +0.2%, NSA +0.1%, FCPT +0.1%, VICI +0.1%

Companies trading higher in after hours in reaction to news: BB +8.5% (considering strategic alternatives for its businesses), CHEF +3.8% (acquires Hardie's Fresh Foods and Greenlead Produce & Specialty Foods), EDIT +2.3% (study of SLEEK published), BOC +1.9% (increases ownership to 100% in 24th Street Asset Management), WTRG +1.6% (subsidiary acquires wastewater system), DDD +1% (acquiring Wematter), ADSE +0.4% (delaying filing 20-F), NOG +0.2% (increases dividend)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: CHGG -32.3%, ETWO -17.2%, CYH -12.9%, ANET -7.6%, MED -7.6%, CACC -6.8%, CNO -6.3%, AXNX -6.2%, SYK -5.3%, SGRY -4.2%, RE -3.5%, RMBS -2.7%, VRTX -1.7%, FANG -1.7%, ADUS -1.6%, JJSF -1%, CAR -0.9%, FMC -0.6%, VRNS -0.3%, SYM -0.3%, SBAC -0.1%, INST -0.1%, SCI -0.1%

Companies trading lower in after hours in reaction to news: TVTX -24.8% (topline primary efficacy results from Phase 3 DUPLEX study), MLTX -2.2% (files mixed shelf), CIFR -1.4% (announces April 2023 production), SPWR -0.9% (appoints new COO), TMUS -0.1% (files mixed shelf; files stock offering)

(ZH) ISM Manufacturing Screams Stagflation, Still Contracting With "Reigniting I

ISM Manufacturing Screams Stagflation, Still Contracting With "Reigniting Inflationary Pressures"

Following S&P Global's manufacturing survey's surprise jump in the flash data, the 50.4 print has dropped intra-month to 50.2 (still back in expansion)
  • S&P Global US Manufacturing final April print of 50.2, down from 50.4 flash, up from 49.2 in March - highest since Oct 2022
  • ISM US Manufacturing April print of 47.1, up from 46.3 prior (and betyer than the expected 46.8) - but still in contraction (sub-50).
Given the notable slide in the US macro surprise index
Source: Bloomberg
Chris Williamson, Chief Business Economist at S&P Global Market Intelligence, said:
“US manufacturing output has regained some encouraging momentum at the start of the second quarter, having stabilised in March after four months of decline.
“While the upturn is in part linked to greatly improved supply chains, helping reduce backlogs of orders, April also saw a welcome upturn in new order inflows for the first time since last September.
“Although only modest, the rise in new orders hints at a tentative revival of demand, notably from consumers but there are also signs that fewer customers are deliberately winding down their inventory levels.
“The brightening demand picture was accompanied by a lifting of business confidence about the outlook and increased hiring. The downside was a reigniting of inflationary pressures, with a stronger order book encouraging more firms to pass through higher costs to customers.”
Economic activity in the manufacturing sector contracted in April for the sixth consecutive month following a 28-month period of growth, say the nation's supply executives in the latest Manufacturing ISM Report.
“Of the six biggest manufacturing industries, two - Petroleum & Coal Products; and Transportation Equipment - registered growth in April."
“New order rates remain sluggish as panelists remain concerned about when manufacturing growth will resume. Panelists’ comments registered a 1-to-1 ratio regarding optimism for future growth and continuing near-term demand declines. Supply chains are prepared and eager for growth, as panelists’ comments support reduced lead times for their more important purchases. Price instability remains and future demand is uncertain as companies continue to work down overdue deliveries and backlogs. Seventy-three percent of manufacturing gross domestic product (GDP) is contracting, up from 70 percent in March.
However, fewer industries contracted strongly; the proportion of manufacturing GDP with a composite PMI® calculation at or below 45 percent — a good barometer of overall manufacturing weakness — was 12 percent in April, compared to 25 percent in March,” says Fiore.
Prices Paid back above 50...
Source: Bloomberg
So ISM screams stagflation - no growth and higher prices.

WSJ : Another Drug Captures Attention in the Fight Against Aging

Another Drug Captures Attention in the Fight Against Aging
Longevity seekers are captivated by a transplant drug called rapamycin, but many doctors are wary

A kidney transplant drug has become the latest fixation of people trying to fight aging.

Some people looking to extend their lifespan have for years turned to a decades-old diabetes drug, metformin. Now, rapamycin, an immunosuppressant medication, is capturing their attention because some aging researchers believe it holds more promise.

Rapamycin was originally approved by the U.S. Food and Drug Administration to prevent organ rejection in kidney transplant patients. Scientists have studied its potential to fight aging, too, and animal studies of rapamycin have yielded encouraging results, although there is little evidence of its longevity benefits in humans.

Rapamycin’s antiaging potential has attracted more off-label users in the last five years, especially among self-described “biohackers” who relish data-driven experiments to optimize health, according to aging researchers and longevity doctors. Yet its side effects can be serious, and most doctors are wary of prescribing it off-label.

Deepak Chopra, the 76-year-old alternative health and wellness author with millions of social media followers, is among rapamycin’s high-profile users. He says he has taken 6mg of the drug a week for the last year and a half as part of a longevity regimen that includes supplements and two hours of yoga a day.

Efforts to fight aging
Longevity research is challenging because it is hard to prove that one particular drug or action is responsible for extending a healthy lifespan, especially in humans, who live for decades. Some measures and medications initially yield promising results only to come up short later.

Recent studies have damped some of the enthusiasm among some biohackers and longevity researchers for the diabetes drug metformin. The more recent buzz around rapamycin has caught the eyes of biotechnology investors. Last year, Cambrian Bio, a clinical-stage biotech company, announced a licensing deal with pharmaceutical company Novartis AG aimed at identifying a compound with longevity benefits similar to those of rapamycin with fewer serious side effects.

Studies have suggested that rapamycin can extend the lifespan of yeast, worms and flies. Studies in mice, including by the National Institute on Aging’s Interventions Testing Program in 2009, have also shown an increase in lifespan.

Rapamycin is part of a group of drugs known as mTOR inhibitors. The drugs curb a cellular pathway that is responsible for cell growth in mammals. Aging researchers have found slowing down cell growth can help prevent chronic inflammation and spur autophagy, or the process of cleaning out damaged cells.

Autophagy naturally decreases with age, which can lead to a buildup of cellular “junk” that makes it harder for cells to repair themselves and work efficiently, says researcher Matt Kaeberlein, who co-directs the Dog Aging Project, a research project that includes a clinical trial on the effects of rapamycin in dogs.

Reducing inflammation and clearing away damaged cells could help prevent or delay the development of age-related disease such as cancer, researchers say.

Weighing the risks
Most doctors remain cautious.

Rapamycin’s FDA label warns users may become more susceptible to infection and the possible development of lymphoma, noting that only physicians who are experts in immunosuppressive therapy should prescribe it. Research on transplant patients, who often take higher, more frequent doses of the drug compared with those who take it for longevity, showed some of the most common side effects were high blood pressure and cholesterol levels, mouth ulcers, and the loss of kidney function.

That hasn’t thwarted the enthusiasm for the drug within the biohacking community and among some scientists who study aging, who say that taking a weekly dose of the drug—rather than daily, as most transplant patients do—may reduce negative side effects and even improve immune response.

Some doctors at longevity-focused clinics and telehealth apps say they are writing off-label prescriptions to patients. The drug, also called sirolimus, is sold by Pfizer Inc. under the brand name Rapamune and multiple drugmakers produce its generics. An off-label monthly supply of the drug can cost between around $150 for generics and about $1,000 for the brand-name product. Some are turning to digital pharmacies outside of the U.S. that sell the drug for much less.

A spokeswoman for Pfizer says the company doesn’t support off-label use of any of its medicines. The FDA says doctors are generally allowed to prescribe drugs for nonapproved uses if they think it makes sense. The agency doesn’t vouch for the safety or effectiveness of medications used off-label.

Interest from longevity-seekers
Robin Young, an AI and biotech entrepreneur, started experimenting with various doses of rapamycin about two years ago in an attempt to determine what would work best for him. At the highest dose he tried, 20mg a week, he recalls getting several bad sinus infections.

Now, Mr. Young, who is based between Singapore and the Pacific Northwest, takes a lower dose every few weeks and avoids taking it at all when he’s traveling because of the added stress to his body. He worries about potential side effects such as high cholesterol but says he feels compelled by the potential benefits around cancer prevention.

“I want to avoid these chronic diseases as much as possible,” says Mr. Young, 42, whose mother died of ovarian cancer when he was young.

Dr. Bradley Rosen, a physician who runs a longevity-focused practice in Los Angeles, says rapamycin is the drug patients ask about most often. Dr. Kaeberlein, the aging researcher, says he gets “contacted once a week by someone who’s a CEO or a major partner in a venture-capital fund because they’re taking it.”

Dr. Alan Green, who runs a longevity-focused practice in Queens, N.Y., says he has prescribed rapamycin off-label to more than 1,200 patients. The most common side effect he has observed is an increased risk of bacterial infections. He recommends patients not start taking the drug unless they have antibiotics on hand.

AgelessRx, a telemedicine platform that prescribes longevity treatments, is running a randomized controlled trial with 150 participants to study how taking rapamycin affects visceral fat, or fat stored deep around the organs, which tends to increase as people age.

Krister Kauppi, a systems developer and biohacker in Gothenburg, Sweden, says he has taken rapamycin for longevity for roughly three months, even as questions remain about its long-term effectiveness and safety.

“It’s still guesswork; we don’t know how well it will work on humans or not,” he says. “From a risk-benefit calculation perspective, I have decided that the benefits outweigh the risk.”

WSJ : Israeli Startups Struggle to Raise Money Amid Political Turmoil, Global Do

Israeli Startups Struggle to Raise Money Amid Political Turmoil, Global Downturn
Tech hub saw 70% drop in funding in the first quarter and underperformed worldwide average

TEL AVIV—Israeli technology companies are struggling to raise funds, recent data shows, amid a combination of global economic trends and investor concerns over how a proposal to overhaul the country’s judiciary could affect the sector, one of the world’s most vibrant hubs for startups.

Israeli technology companies were hurt harder in the first quarter than other global tech hubs, data shows, suggesting the reasons behind the decline in fundraising go beyond macroeconomic conditions.

The global technology sector has suffered as investors pull back due to higher interest rates, a trend Israeli venture capitalists and technology companies say they are also feeling. Some are also saying investor confidence has been hit by the political turmoil sparked by Prime Minister Benjamin Netanyahu’s plan to overhaul the country’s judicial system. The proposal—which aims to weaken the top court and give more power to lawmakers—has sharply divided the country and driven hundreds of thousands of Israelis to protest the initiative for months.

“It is a double catastrophe, a perfect storm,” said Shlomi Uziel, the co-founder of Quai.MD, an early-stage health-tech company. Mr. Uziel said he recently took a funding deal that slashed his company’s valuation. “I’m considered lucky because I actually had an offer.”

In the first quarter of 2023, Israeli technology companies raised $1.7 billion, a 70% drop from the first quarter of 2022 and the lowest quarterly fundraising level in four years, according to a report released in April by the Tel Aviv-based IVC Research Center.

Globally, funds raised by technology startups decreased 13% in the first quarter of 2023 from the previous quarter, according to the analytics firm CB Insights. In Europe, fundraising fell by 12% in the same period and in the U.S. it declined by 1%, CB Insights found. In Israel, funds raised over the same period decreased by 20%, according to the IVC Research Center.

Israel’s tech sector is one of the world’s largest technology hubs, especially for startups. Companies in Tel Aviv, the center of Israel’s tech industry, raised $6.9 billion from venture-capital firms in 2022, the third-highest of any European, African or Middle Eastern tech hub, according to Dealroom, a tech-analytics company. London, followed by Paris, topped the list.

A dent to the tech industry in Israel—nicknamed Startup Nation—would also have an outsize effect on the country’s economy. The sector makes up around 16% of Israel’s gross domestic product and around half of its exports.

“We are today in the middle of a global crisis, and it is still too early to know when and how it will end. Added to this is a local crisis that has created additional uncertainty,” said Dror Bin, head of the Israeli Innovation Authority, a government body tasked with growing Israel’s technology sector.

Mr. Bin’s comments came in a paper released by the authority on Monday that warned Israel’s tech sector is endangered by a severe decline in funding, a growing negative gap between returns for Israel’s technological stock index in Tel Aviv and the Nasdaq, and an increase in Israeli-led companies being established abroad.

“Even if the legal-judicial crisis is solved, it will take time to reach a solution, and even after this, it will take time to build confidence with investors once more,” Mr. Bin said.

Analysts, entrepreneurs and venture capitalists said the majority of the decrease in fundraising likely stems from the challenging macroeconomic environment. While it is difficult to determine the impact of the political situation, some entrepreneurs say investors explicitly cited the upheaval as a reason for pausing or decreasing the size of investments.

Many in the industry said the second and third quarters will provide a clearer picture because deals reported in the first quarter may have been in the works before the judicial overhaul was announced.

The sudden collapse of Silicon Valley Bank in March could also hurt future fundraising for Israeli technology companies.

The bank was one of the most prolific lenders in Israel’s tech industry, and its absence will create even rougher conditions for companies by forcing them back into the challenging equity market, said Adam Fischer, a partner at venture-capital firm Bessemer Venture Partners.

Ilan Samish, the chief executive officer and founder of Amai Proteins, a food-tech startup that produces an artificial protein sweetener, said his recent fundraising efforts had been hit by multiple factors.

He said his company was in the final stages of closing a $100 million funding round in December when the lead investor pulled out due to global economic uncertainties.

At the end of January, Mr. Samish said he brought an investor to Israel who had little knowledge of the country, but was interested in his company. But at the time, Israel was engrossed in internal upheaval caused by opposition to the overhaul.

“Things are turbulent, so I’m closing my pocket until things settle down,” Mr. Samish said he heard from the investor.

Israel’s technology sector has become a prominent actor in the movement against the judicial overhaul that has produced some of the largest protests in the country’s history. The heads of many tech companies have said Israel’s internal instability has become a common topic in conversations with investors.

Mr. Netanyahu has paused the judicial legislation to give time for negotiations with the opposition. Meanwhile, demonstrations against the overhaul have continued, drawing over 100,000 weekly protesters in Tel Aviv.

In April, Moody’s Investors Service joined prominent economists in the U.S. and Israel, including from the country’s central bank, in warning that the government’s proposed judicial overhaul could harm the country’s economic outlook. The agency reaffirmed Israel’s A1 rating, but revised its outlook from positive to stable, a sign it could downgrade the country’s rating in the future.

Some Israeli tech executives say the country’s politics haven’t affected their business.

Didier Toubia, CEO of Aleph Farms, a leading food-tech company in Israel, said that current challenges boiled down to the global macroeconomic environment.

“There might be some perception of Israel-specific risk by some investors. But it is a misperception. The polarization we see in Israel isn’t different from what we see in the U.S. or in France,” said Mr. Toubia, who is originally from France.

Start-Up Nation Central, a Tel Aviv-based nonprofit that tracks tech investments, released a survey in April that found that 84% of investors believe the judicial changes will have a negative effect on their ability to raise capital from abroad.

Israel’s tech industry has shown resilience in the past, including weathering the hit of the dot-com bust at the turn of the millennium, which coincided with a yearslong bloody battle with Palestinians known as the Second Intifada.

Avi Hasson, head of Start-up Nation Central, said the current crisis, which he also called a “perfect storm,” poses a risk to the long-term health of the technology ecosystem because companies are starting to move capital, intellectual property, and talented employees outside of Israel.

The Start-up Nation Central survey found that 78% of investors want their portfolio companies based outside of Israel. It found that 27% of companies are considering relocation packages to move employees outside of Israel, and 35% of those are actively planning to do so.

“The most important ingredient to Start-up Nation is talent. We need to protect it at all costs,” he said.

Erel Margalit, founder and executive chairman of one of Israel’s largest venture-capital firms, Jerusalem Venture Partners, said Israel’s political turmoil is a challenge for the technology sector, but the move to incorporate or move employees abroad will make the firms more global.

“When it comes out of the political crisis, it will be even stronger, and it will be more international,” he said.

FT : S&P criticised by pension funds over dual-class shares decision

S&P criticised by pension funds over dual-class shares decision
Move to reopen S&P 500 and other indices to companies with multiple share class structures draws backlash

Large pension funds are demanding answers from S&P Global about its decision to allow companies with unequal shareholder voting rights into its popular indices, a move that allows private equity giants Blackstone and Ares to join the S&P 500.

The Council of Institutional Investors, which represents pension funds and has advocated against unequal voting rights, said it “was surprised and disappointed” by S&P’s decision on April 17 to reopen the S&P 500 and other indices to companies with multiple share class structures, according to an April 25 letter to S&P seen by the Financial Times.

“We were also disappointed by the opaque process S&P Dow Jones used to reach its decision,” CII said, asking for a meeting with company officials.

S&P’s change reverses a five-year-old policy of barring new companies with dual-class shares from indices. S&P initially banned dual-class companies in 2017 after Snap, the owner of the Snapchat app, went public with no voting rights, sparking an uproar from pension funds. S&P’s prohibition did not force out existing constituents such as Alphabet, Berkshire Hathaway and Meta.

For decades, institutional investors and companies have warred over dual-class shares. This set-up was typically used by family-controlled companies such as Ford and the New York Times to preserve family control over the businesses by selling stock with significantly less voting power.

In recent years, more initial public offerings have increasingly included dual-class shares, especially since Google’s controversial dual-class float in 2004. Pension funds and other big investors have attacked dual-class shares for undercutting their sway over boards. There are at present 27 dual-class share companies in the S&P 500, according to ISS Corporate Solutions. More than 100 companies are now eligible for S&P 500, the mid-cap 400 and small-cap 600, according to Keefe, Bruyette & Woods, an investment bank.

Investors said they were caught off guard by the S&P’s decision.

“We were deeply dismayed to hear of S&P’s retrograde decision” on multiple class shares, said Caroline Escott, senior investment manager at Railpen, which manages £35bn for British railway workers.

“It is currently unclear the extent to which the wider investment industry was appropriately consulted during the decision-making process over the last few months,” she said. “We are writing to S&P to ask for further information.”

S&P said the company occasionally reviews its index methodologies and the change on multiple class shares was a result of a public consultation last year with market participants.

Changes in markets and investor sentiment since 2017 meant that restricting multi-class companies “no longer served the index family’s objective”.

“Companies with multiple share classes are part of the total investable universe and should be eligible for potential addition,” it said.

S&P’s rule change means Ares and Blackstone could soon join the benchmark S&P 500 index, KBW said in an April 19 report. Blackstone was probably already eligible, KBW said, but S&P’s rule change “removes any uncertainty” about the private equity group’s eligibility.

“We have the largest market capitalisation of any company in the US not in the S&P 500,” Blackstone president Jon Gray said in an interview with the FT last week.

Jill Fisch, a corporate governance scholar at the University of Pennsylvania law school who has published research about dual-class share companies, said S&P’s prohibition on dual-class shares in 2017 did not deter companies from going public with the structure in recent years.

And there is an argument that small investors missed out on performance opportunities when dual-class share companies were banned by S&P. Companies such as Peloton and Uber were reined in by the market even though they had dual-class shares that protected founders, she said.

Ultimately, the ebb and flow of the stock market was likely to determine how many companies will try to go public with unequal voting rights, she said.

“In a tougher market for IPOs or a tougher equities market overall I think we can expect to see fewer dual-class IPOs,” she said.

>>> US Research Calls

Research Calls

  • Upgrades:
    • Alignment Healthcare (ALHC) upgraded to Outperform from Mkt Perform at Raymond James; tgt $9
    • Allbirds (BIRD) upgraded to Outperform from Market Perform at Telsey Advisory Group; tgt $1.50
    • AvalonBay (AVB) upgraded to Neutral from Underweight at Piper Sandler; tgt raised to $193
    • Banco Bilbao Vizcaya Argentaria (BBVA) upgraded to Buy from Hold at HSBC Securities
    • Biogen (BIIB) upgraded to Buy from Neutral at Guggenheim; tgt raised to $350
    • Carter Bank & Trust (CARE) upgraded to Outperform from Mkt Perform at Raymond James; tgt $17
    • Comcast (CMCSA) upgraded to Buy from Neutral at BofA Securities; tgt raised to $49
    • General Motors (GM) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $38
    • IAMGOLD (IAG) upgraded to Outperform from Market Perform at BMO Capital Markets; tgt raised to $3.25
    • Logitech Int'l SA (LOGI) upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $56
    • Manitowoc (MTW) upgraded to Equal Weight from Underweight at Wells Fargo; tgt raised to $17
    • Otis Worldwide (OTIS) upgraded to Equal Weight from Underweight at Wells Fargo; tgt raised to $88
    • Scotts Miracle-Gro (SMG) upgraded to Buy from Hold at Stifel; tgt raised to $80
    • Teradata (TDC) upgraded to Buy from Neutral at Guggenheim; tgt $62
    • Zillow (ZG) upgraded to Mkt Perform from Underperform at Bernstein; tgt raised to $45
  • Downgrades:
    • ArcBest (ARCB) downgraded to Underperform from Neutral at BofA Securities; tgt lowered to $91
    • Banco Santander (SAN) downgraded to Hold from Buy at HSBC Securities
    • Doximity (DCOS) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $37
    • Exxon Mobil (XOM) downgraded to Neutral from Buy at Goldman; tgt $125
    • IVERIC bio (ISEE) downgraded to Neutral from Buy at Guggenheim
    • Principal Fincl (PFG) downgraded to Neutral from Buy at BofA Securities; tgt lowered to $78
    • South Atlantic Bancshares (SABK) downgraded to Neutral from Buy at Janney; tgt lowered to $14
    • Valley National (VLY) downgraded to Mkt Perform from Strong Buy at Raymond James
  • Others:
    • Danaher (DHR) initiated with an Outperform at SVB Securities; tgt $300
    • Edgewise Therapeutics (EWTX) initiated with a Buy at Truist
    • Endeavor Group (EDR) initiated with a Buy at Guggenheim; tgt $33
    • Immunovant Sciences (IMVT) initiated with a Buy at BofA Securities; tgt $26
    • MoonLake Immunotherapeutics (MLTX) initiated with a Buy at Guggenheim; tgt $51
    • TD Synnex (SNX) initiated with a Buy at Goldman; tgt $101
    • Treace Medical Concepts (TMCI) initiated with a Buy at Truist; tgt $33